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Summary
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is
mainly reported in patients with bone metastasis from a vari-
ety of solid tumors and disseminated multiple myeloma re-
ceiving iv bisphosphonates therapy. These patients represent
95% of reported cases. The reported incidence of BRONJ is
significantly higher with the iv preparations zoledronic acid
and pamidronate while the risk appears to be minimal for pa-
tients receiving oral bisphosphonates. Currently, available
published incidence data for BRONJ are based on retrospec-
tive studies and estimates of cumulative incidence range from
0.8% to 12%. The mandible is more commonly affected than
the maxilla (2:1 ratio), and 60% of cases are preceded by a
dental surgical procedure. The signs and symptoms that may
occur before the appearance of clinical evident osteonecrosis
include changes in the health of periodontal tissues, non-heal-
ing mucosal ulcers, loose teeth and unexplained soft-tissue
infection. Although the definitive role of bisphosphonates re-
mains to be elucidated, the alteration in bone metabolism to-
gether with surgical insult or prosthetic trauma appear to be
key factors in the development of BRONJ. Tooth extraction as
a precipitating event is a common observation in the reported
literature. The significant benefits that bisphosphonates offer
to patients clearly outbalance the risk of potential side effects;
however, any patient for whom prolonged bisphosphonate
therapy is indicated, should be provided with preventive den-
tal care in order to minimize the risk of developing this severe
condition. This article provides a review of current develop-
ments about the pathogenetic, clinical, management and pre-
ventive aspects of BRONJ. 
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Nitrogen-containing bisphosphonates are used widely for the
treatment of bone metastasis (intravenous zolendronic acid or
pamidronate), for the prevention and treatment of osteoporosis
(oral alendronate, risendronate, and ibandronate and intra-
venous ibandronate), for the treatment of Paget’s, and for the
short- term management of acute hypercalcemia (intravenous
zolendronic acid and pamidronate). 
In 2003, after an alert initial observation by Wang et al. (1) at
the University of California San Francisco, Rosenberg and
Ruggiero (2), Marx (3) and Migliorati (4) have reported unusual
findings of osteomyelitis – like lesions of the jaws in a set of pa-
tients affected by multiple myeloma and metastatic bone dis-
ease; subsequentely, several papers have confirmed the initial
observations and called this condition as bisphosphonate-relat-
ed osteonecrosis of the jaws (BRONJ) (5-23). All the initial ob-
servations have pointed to the potential role of the intravenous-
ly administered bisphosphonates such as pamidronate and
zoledronate. Additionally, BRONJ has been reported in a small
number of patients (until now at least 35 cases) who had re-
ceived oral non nitrogen-containing bisphosphonates for both
cancer and non-cancer conditions (5, 10, 16, 24-27). Currently,
available published incidence data for BRONJ are based on
retrospective studies and estimates of cumulative incidence
range from 0.8% to 12%.
It is of historical interest to mention that osteonecrosis of the
jaws was observed in the 19th and early 20th centuries in pa-
tients exposed to white phosphorus. At that time the disease
was called phossy jaw or phosphorus necrosis and was mainly
observed in people working in the matchmaking and fireworks
factories or brass and war munitions industries (28). Amazing-
ly, clinical descriptions of phossy jaw lesions overlap those re-
ported today in cases of BRONJ (29).
Based on the available data, this review discusses the patho-
genetic, clinical, management and preventive aspects of
BRONJ. 
Pathogenesis
From what it is known up to date it seems that the pathogene-
sis of BRONJ is due to a defect in jawbones physiologic re-
modelling and wound healing. The negative impact of bisphos-
phonates on bone physiology centers on osteoclast inhibition
and apoptosis. The damaged osteoclast function affects the
normal bone turnover and resorption process while additional
negative effects of bisphosphonates also relate to depressed
blow circulation in bones. In addition, bisphosphonates have
the capability to inhibit endothelial cell function in vitro and in
vivo and also demonstrate antiangiogenic properties because
of their capacity to decrease circulating levels of the potent an-
giogenic factor VEGF (reviewed in 16-18, 20, 30).
On the base of the current knowledge, BRONJ seems to be an
exclusive ailment of the jaw bones. Most cases of BRONJ de-
velop in patients who have undergone tooth extraction or other
forms of surgical procedures; however a certain number of
both edentulous or dentate patients has developed necrotic
bone spontaneously. This apparent and exclusive involvement
of the jaw bones may be a mirror of the uniqueness of the oral
environment. It is well known that in normal conditions healing
of a wound of the jaw bones (e.g., extraction socket) occurs
quickly and without complication. Instead, in patients who have
received tumoricidal irradiation (and/or other toxic agents) of
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the mandible and maxilla the healing process and the vascular
supply of these bones are compromised, then even minor in-
jury or inflammatory/infective diseases in these sites increases
risk for osteonecrosis and osteomyelitis. In relation to the nega-
tive effects of bisphosphonates, it is conceivable that, because
the jaw bones are sites of high bone turnover, these drugs con-
centrate within the bone tissue. This may partially explain the
selective preference of bisphosphonates osteonecrosis for the
jaw bones (reviewed in 16-18, 20, 30). 
Clinical and radiographic features
Patients with BRONJ are typically oncology patients with multi-
ple myeloma or metastatic disease involving bone. The clinical
aspects and behaviour of BRONJ show a striking resemblance
to osteoradionecrosis with exposed bone and sequestration
non-responsive to conventional surgical management. BRONJ
may be asymptomatic for long time or may result in pain or ex-
posed maxillary or mandibular bone (Fig. 1). Typical signs and
symptoms are pain, soft-tissue swelling and infection, loosen-
ing of teeth and draining fistula. Patients may have other symp-
toms such as difficulty in eating, speaking, and clinical signs
such as trismus, halitosis and recurrent abscesses. Some pa-
tients may present with atypical symptoms such as “dull pain”,
numbness, the feeling of “bigger jaw” or lower-lip paresthesia.
The signs and symptoms that may occur before the appear-
ance of clinically evident BRONJ include changes in the health
of periodontal tissues, non-healing mucosal ulcers, loose teeth
and unexplained soft-tissue infection (5, 9, 10). Chronic maxil-
lary sinusitis secondary to BRONJ with or without oro-antral fis-
tula can be the presenting symptom in patients with maxillary
involvement.
Since 2003, about 1000 cases of BRONJ of the jaws have
been reported in the English-language literature, the majority
associated with the use of iv bisphosphonates (19,20,22).
Anatomic location may be unilateral or bilateral with 63% to
68% affecting only the mandible, 24% to 28% of cases involv-
ing only the maxilla, and 4.2% both jaws. The mean number of
involved areas was 2.3 per each affected patient, with each
site having an average size of 2 cm. Unusual cases of extrag-
natic location in the external auditory canal have been ob-
served (31, Ficarra, personal observation). Ruggiero et al. (5)
have observed pathologic fracture of either the maxilla or
mandible in 8% of patients treated with nitrogen-containing bis-
phosphonates; rare cases of bilateral pathologic fractures of
both jaws also have been reported. Extraoral fistula formation
and sequestration through the skin are infrequently observed.
Radiographic alterations are not evident until there is signifi-
cant bone involvement. Early stages of BRONJ may not reveal
any significant changes on panoramic and periapical films.
Late radiographic changes may mimic classic periapical inflam-
matory lesions or osteomyelitis. Other radiographic findings in-
clude non-healing extraction site, widening of the periodontal
ligament space and osteosclerotic lamina dura (16-18, 20, 30).
In cases of extensive bone involvement, areas of mottled bone
similar to that of diffuse osteomyelitis become evident (Fig. 2).
In cancer patients some of these changes may raise the suspi-
cion of myeloma or metastatic bone lesion (18). Involvement of
the inferior alveolar canal can be associated with paresthesia
of the lower lip. Bone scan with Tc-99m methylene diphospho-
nate often shows intense uptake in or around the lesional area,
indicating active bone turnover.
Risk factors
Recent retrospective studies and review papers have identified
and discussed several risk factors associated with BRONJ (5,
7, 9-23). Major factors are a history of dental extractions, dura-
tion of bisphosphonates treatment, and the type of bisphospho-
nates. The majority of reported BRONJ cases are associated
with recent dentoalveolar surgery. This fact underlines the rele-
vant importance of optimal good health and avoiding extrac-
tions especially in cancer patients receiving nitrogen-containing
bisphosphonates. However, lesions may also occur sponta-
neously in non extractive sites such as dentate or non dentate
areas or in areas covered by prosthetic appliances. The phe-
nomenon of spontaneous appearance of BRONJ may be ex-
plained by the fact that, once “metabolically damaged” by the
treatment with bisphosphonates, the jaw bones remain suscep-
tible even to minor causative factors such as prosthetic trauma
(5, 10). 
The duration of bisphosphonates therapy is also an important
factor which relates to the likelihood of developing BRONJ. In
addition, the more potent nitrogen-containing bisphosphonates,
such as pamidronate and zoledronate, are significantly associ-
ated with the development of BRONJ than the oral bisphospho-
nates formulations (15-23). A recent prospective study as-
sessed BRONJ in patients who received bisphosphonates
since January 1997 (32). BRONJ was diagnosed in 17 of 252
patients. In addition, the study showed that the duration of iv
bisphosphonate therapy appeared to be the most important
risk factor.
A variety of etiological factors such as radiation and corticos-
teroid treatment, trauma, smoking, alcohol abuse, poor oral hy-
giene, herpes zoster, HIV infection and fungal infections, and
predisposing conditions such as diabetes, osteopetrosis, fibrous
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Figure 1 - Extensive osteonecrosis in the maxilla with large sequestrum.
Figure 2 - A panorex reveals the presence of a mottled zone of bone
necrosis involving both the right maxilla and mandible. Note the large
sequestrum in the right mandible.
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dysplasia, may also affect wound healing of the jaws bones and
also must be considered as possible cofactors (9, 17).
In summary, the fact that the majority of BRONJ cases are asso-
ciated with the use of iv bisphosphonates for multiple myeloma
and metastatic bone diseases suggests that dosage, length of
treatment, and route of administration, as well as cofactors such
as use of glucocorticoids and immunosuppressive agents, and
dental surgery, could all be related to the incidence of this ailment. 
Pathology 
Diagnosis of BRONJ should be mainly based on clinical and ra-
diographic criteria. Tissue biopsy is not always necessary and
should be performed only if metastatic disease is suspected. At
microscopic examination, the specimen shows areas of necrotic
bone and debris and fibrinous exudates accompanied by a poly-
morphonuclear leukocyte infiltrate (Fig. 3). The nonvital bone
exhibits loss of osteocytes from the lacunae, peripheral resorp-
tion and bacterial colonization. Scattered sequestra and pockets
of abscess formation are common. These features are similar to
those observed in chronic osteomyelitis (9, 16-18). 
Microbial cultures (aerobic and anaerobic) may provide identifi-
cation of pathogens causing secondary infection. Microbiologi-
cal investigations have detected a variety of oral pathogens
such as Actinomyces, Enterococcus, Candida albicans,
Haemophilus influenza, alpha-haemolytic streptococci, Lacto-
bacillus, Enterobacter and Klebsiella pneumoniae, etc. (23).
However, it is important to stress that cultures taken from an
open sinus tract or exposed jaw bone may give misleading re-
sults because the isolates may include non-pathogenic mi-
croorganisms that are colonizing the site (33). Several authors
have found a striking high presence of Actinomyces in necrotic
bone areas and considered these pathogens to be involved in
the chronic, non healing process of BRONJ (11, 18, 23, 34). 
Case definition and staging of BRONJ
In order to establish rational treatment guidelines and collect
clinical information to assess the prognosis in patients with
BRONJ a working definition and staging system have been
proposed by some researchers or association such as the
American Association of Oral and Maxillofacial Surgeons
(AAOMS) and the Novartis Pharmaceuticals Corporation (18,
22, 35).
To distinguish BRONJ from other delayed healing entities, the
AAOMS (35) has adopted the following working definition. Pa-
tients may be considered to have BRONJ if all of the following
three characteristics are present: a) past or current therapy
with bisphosphonates; b) presence of exposed, necrotic bone
in the maxillofacial region that has persisted for more than 8
weeks; and c) absence of history of radiation treatment to the
jaw bones. The staging system reported here is the one which
has been proposed by the AAOMS (Table I). In stage 1 the dis-
ease is characterized by exposed bone and absence of symp-
toms. Patients at this stage usually do not require treatment.
However, it is relevant to note that some patients my have pain
prior to the appearance of radiographic or clinical signs of overt
BRONJ. Patients in stage 2 show exposed bone with associat-
ed pain. This stage requires antimicrobial therapies, pain con-
trol and superficial debridement to relieve soft tissue irritation.
Stage 3 is characterized by exposed bone associated with
pain, adjacent or regional soft tissue swelling and signs of sec-
ondary infection resistant to antibiotic treatment. These pa-
tients, because of voluminous sequestra, often require surgical
intervention to debride necrotic bone.
Figure 3 - High-power photomicrograph of biopsy tissue showing irregular
fragments of nonvital bone that exhibit peripheral resorption, empty os-
teocytic lacunae and polymorphonuclear leukocyte infiltrate (H&E, 400x).
Table I - Clinical Staging of BRONJ and treatment guidelines*.
Stages Treatments guidelines
At risk category: no apparent exposed/necrotic bone in patients No treatment indicated
treated with either oral or iv bisphosphonates Patients education
Stage 1: exposed/necrotic bone in patients who are asymptomatic Antibacterial mouth rinse
and have no evidence of infection Clinical follow-up every 4 months
Stage 2: exposed/necrotic bone associated with infection. Treatment with broad-spectrum oral antibiotics*
Presence of pain and erythema in the lesional area with or Antibacterial mouth rinse
without purulent drainage irritation Pain control
Superficial debridement to relieve soft tissue
Stage 3: exposed/necrotic bone in patients with infection and pain. Antibacterial mouth rinse
Presence of one or more of the following: pathologic fractures, Antibiotic therapy and pain control
extraoral fistula, or osteolysis extending to the inferior border Surgical debridement/resection for longer term palliation of
infection and pain
* Modified from reference 35. 
** Penicillin, amoxicillin/clavulanate potassium, metronidazole, cephalexin, clindamycin, fluoroquinolone.
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Management guidelines for patients treated 
with bisphosphonates
Preventive aspects
It is important to underline that a strict collaboration between
the dentist and the clinician/oncologist is mandatory in order to
identify strategies to improve the care of patients treated with
bisphosphonates. Until we have a better understanding of the
role of bisphosphonates in the pathobiology of BRONJ it is a
must that preventive measures be always taken in order to pre-
vent the risk of developing this severe ailment. These include
careful dental examination and mandatory extractions of candi-
date teeth with enough time allowed for healing in advance of
the start of bisphosphonate treatment (9). Based on previous
experience with osteoradionecrosis, it is highly advisable that
bisphosphonates therapy should be delayed until there is ade-
quate bone healing (18). Of great importance is the adoption of
preventive measures such as dental caries and periodontal dis-
ease control, conservative restorative dentistry, avoiding dental
implant placement, and the use of soft liners on dentures. This
level of care must be continued indefinitely (9, 18).
In asymptomatic patients receiving iv bisphosphonates pre-
venting dental diseases that may require dentoalveolar surgery
is of pivotal importance. In these patients any procedure that
may cause direct osseous damage must be avoided as well as
placement of dental implants. Non-restorable teeth should be
treated by removal of the crown and endodontic treatment of
the root remnants.  
Patients receiving oral bisphosphonates have a much lesser
risk of developing BRONJ than those treated with iv bisphos-
phonates. The risk of BRONJ may be associated with longer
duration of therapy (i.e., 3 years or more); however it is impor-
tant to stress that this point needs further research and clarifi-
cation. In general, these patients seem to have a less severe
form of BRONJ and show a better response to stage-specific
treatment strategies. In this group, dental extractions are not
contraindicated. It is however recommended that patients
should be adequately informed of the potential, although small,
risk of defective bone healing. Although discontinuation of iv
bisphosphonates in cancer patients has been recommended,
stopping oral bisphosphonates prior to dental surgery cannot
be universally endorsed at this time, since it is unknown
whether this is effective in reducing the risk of BRONJ (36).
Treatment of overt BRONJ
At present, there is no definite treatment for BRONJ. As it is
delineated in Table I, patients with stages 1 and 2 of BRONJ
should be treated using a conservative approach with the goal
of preventing progression of lesions and limiting complications
related to chronic infection. To achieve these goals, conserva-
tive debridement of bone sequestra, local irrigation with povi-
done-iodine and daily rinsing with 0.12% chlorhexidine mouth-
wash, antibiotic therapy and pain control should be considered
(9, 16-18). Surgical debridement has been variable effective in
eradicating the necrotic bone. The goal of surgery should be to
eliminate dead bone which acts as foreign material (34); thus
necrotic areas, that are a constant source of soft tissue irrita-
tion, should be removed or recontoured without exposure of
additional bone. In patients with BRONJ it may be difficult to
obtain a surgical margin with viable bleeding bone as the jaw
bones are metabolically damaged by the bisphosphonates;
therefore aggressive surgical treatment should be delayed if
possible (35). In cases of stage 3 patients with pathologic
mandibular fractures segmental resection and reconstruction
are required. However, because of the potential failure of this
surgical procedure, the patient must be well informed of the
carried risk. Also the immediate reconstruction with non vascu-
larized or vascularized bone may carry the risk of failure as
necrotic bone can develop at the surgical site (35). The efficacy
of hyperbaric oxygen therapy remains uncertain. Some authors
(5) have considered it as not effective and, therefore, did not
recommended it; other authors (6), instead, have found hyper-
baric oxygen therapy of some usefulness. A clinical trial is in
progress in order to establish the efficacy of this treatment
modality for patients with BRONJ (35).  
Although it may seem reasonable and prudent to suggest that
stopping the administration of iv bisphosphonates would im-
prove the resolution rate of this condition, there is no proof to
support such an indication for management. In fact there are
evidences from the published studies that drug withdrawal
does not lead to clinical improvement of BRONJ (16, 17). This
can be well explained by the fact that bisphosphonates avidly
bind to bone mineral around active osteoclasts, resulting in
very high levels in the resorption lacunae. Because bisphos-
phonates are not metabolized, high concentrations are main-
tained within the bone for a long period of time. In cancer pa-
tients with overt BRONJ, the cessation or interruption of bis-
phosphonates must be discussed with the oncologist and al-
ways weighted against the risk of skeletal complications or hy-
percalcemia of malignancy (9, 16, 18). 
Conclusion
BRONJ has been observed in several oral medicine, maxillofa-
cial and oncology departments around the world. Although the
definitive role of bisphosphonates remains to be elucidated, the
alteration in bone metabolism together with surgical insult or
prosthetic trauma appears to be key factors in the development
of osteonecrosis. Tooth extraction as a precipitating event is a
common observation in the reported literature. The reported in-
cidence of BRONJ is significantly higher with the iv prepara-
tions zoledronic acid and pamidronate while the risk appears to
be minimal for patients receiving oral bisphosphonates. The
significant benefits that bisphosphonates offer to patients clear-
ly outbalance the risk of potential side effects; however, any
patient for whom prolonged bisphosphonate therapy is indicat-
ed, should be provided with preventive dental care in order to
minimize the risk of developing this severe condition. Although
discontinuation of iv bisphosphonates in cancer patients has
been suggested, discontinuation of iv bisphosphonates prior to
dental surgery cannot be universally accepted at this time,
since it is unknown whether this is effective in reducing the risk
of BRONJ (36).
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